Skip to main content

Gilead Sciences, Inc.

corporate_fare Company Profile

Gilead Sciences, Inc.

GILD·NASDAQ·Life Sciences·CIK 0000882095

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with its headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included over 25 therapies. Key products with approved indications in the U.S. include: In HIV, Biktarvy® is a once-daily oral single-tablet regimen for HIV-1 infection, combining bictegravir, emtricitabine (FTC), and tenofovir alafenamide (TAF). Descovy® is an oral formulation used with other antiretroviral agents for HIV-1 infection and is also FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in certain patients. Descovy is a fixed-dose combination of FTC and TAF. Genvoya® is a once-daily oral single-tablet regimen for HIV-1 infection, combining elvitegravir, cobicistat, FTC, and TAF. Odefsey® is a once-daily oral formulation for the treatment of HIV-1 infection in certain patients.

Gilead Sciences, Inc. (NASDAQ:GILD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for GILD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for GILD spans 8-K.

Recent high-impact activity:

  • Lenacapavir Doubles One-Year PrEP Persistence vs Daily Pills in PURPOSE 5
  • Livdelzi Hits 75.4% ALP Normalization at Week 52 in Phase 3 PBC Study
  • Gilead Q3 Beats, Lifts 2026 Sales Guidance to $31.0-31.3B, but Loss Outlook Widens
  • Gilead Posts 3Q EPS of $1.94
  • $1.275B Upfront Deal Adds Oral IL-23R Inhibitor to Gilead's IBD Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$29.44B
Net Income
$8.51B
Diluted EPS
$6.78
Op. Cash Flow
$10.02B
Free Cash Flow
$9.46B
Gross Profit
$23.21B
Operating Income
$10.02B
Cash & Equivalents
$7.56B
Total Debt
$24.94B
Debt / Equity
1.10×
Net Margin
28.9%
Shares Outstanding
1.24B sh
Source: 10-K · filed 2026-02-24 · accession 0000882095-26-000006

Short Interest & Short Volume

3.18 days to cover

FINRA reported short interest of 21,271,970 shares in GILD as of the October 30, 2026 settlement, a 4.9% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 50.7% of GILD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)21,271,970 shares as of October 30, 2026
Change vs prior period▲ 4.9%
Days to cover3.18 at avg daily volume of 6,696,858
Daily short volume (FINRA facilities)50.7% of 1,732,649 shares on November 20, 2026
5-day average short volume48.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for GILD, detected from its recent SEC filings.

1 shelf registration

New Shelf Registration Filed · No Immediate Offering

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with G →
$167.58 +0.69% today
52-week range · as of 2026-10-29 $114.02 – $167.58
Market cap
$206.43B
Volume
7.6M (1.2× avg)
3-mo avg 6.4M
Live data · 2026-11-21 16:11 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GILD - Latest Insights

GILD
Nov 06, 2026, 12:16 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $167.82
Real-time Price: $167.58 info
Change: -$0.235 (-0.14%) info
Market Cap: $206.43B info
GILD
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $174.57
Real-time Price: $167.58 info
Change: -$6.98 (-4%) info
Market Cap: $206.43B info
GILD
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $165.88
Real-time Price: $167.58 info
Change: +$1.70 (+1%) info
Market Cap: $206.43B info
GILD
Oct 29, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $164.00
Real-time Price: $167.58 info
Change: +$3.58 (+2%) info
Market Cap: $206.43B info
GILD
Oct 22, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.19
Real-time Price: $167.58 info
Change: +$10.39 (+7%) info
Market Cap: $206.43B info
GILD
Oct 19, 2026, 6:40 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $156.82
Real-time Price: $167.58 info
Change: +$10.76 (+7%) info
Market Cap: $206.43B info
GILD
Sep 21, 2026, 5:20 AM EDT
Source: Moneycontrol
Importance Score:
7
Price at Filing: $149.00
Real-time Price: $167.58 info
Change: +$18.58 (+12%) info
Market Cap: $206.43B info
GILD
Aug 27, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $148.19
Real-time Price: $167.58 info
Change: +$19.39 (+13%) info
Market Cap: $206.43B info
GILD
Aug 24, 2026, 6:31 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $146.80
Real-time Price: $167.58 info
Change: +$20.78 (+14%) info
Market Cap: $206.43B info
GILD
Aug 11, 2026, 4:51 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $135.77
Real-time Price: $167.58 info
Change: +$31.81 (+23%) info
Market Cap: $206.43B info
GILD
Aug 04, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $134.12
Real-time Price: $167.58 info
Change: +$33.46 (+25%) info
Market Cap: $206.43B info
GILD
Aug 04, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $137.42
Real-time Price: $167.58 info
Change: +$30.16 (+22%) info
Market Cap: $206.43B info
GILD
Aug 04, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $135.25
Real-time Price: $167.58 info
Change: +$32.33 (+24%) info
Market Cap: $206.43B info
GILD
Jun 24, 2026, 3:07 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $126.19
Real-time Price: $167.58 info
Change: +$41.39 (+33%) info
Market Cap: $206.43B info
GILD
Jun 23, 2026, 12:50 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $125.55
Real-time Price: $167.58 info
Change: +$42.03 (+33%) info
Market Cap: $206.43B info
GILD
Jun 15, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $124.08
Real-time Price: $167.58 info
Change: +$43.50 (+35%) info
Market Cap: $206.43B info
GILD
Jun 05, 2026, 5:45 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $130.68
Real-time Price: $167.58 info
Change: +$36.90 (+28%) info
Market Cap: $206.43B info
GILD
Jun 05, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $129.70
Real-time Price: $167.58 info
Change: +$37.88 (+29%) info
Market Cap: $206.43B info
GILD
Jun 04, 2026, 4:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $129.18
Real-time Price: $167.58 info
Change: +$38.40 (+30%) info
Market Cap: $206.43B info
GILD
Jun 02, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $130.94
Real-time Price: $167.58 info
Change: +$36.64 (+28%) info
Market Cap: $206.43B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets